Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Finished Goods: 2022-2025

Historic Finished Goods for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $676,178.

  • InMed Pharmaceuticals' Finished Goods fell 68.10% to $295,809 in Q3 2025 from the same period last year, while for Sep 2025 it was $295,809, marking a year-over-year decrease of 68.10%. This contributed to the annual value of $676,178 for FY2025, which is 19.58% down from last year.
  • As of FY2025, InMed Pharmaceuticals' Finished Goods stood at $676,178, which was down 19.58% from $840,812 recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Finished Goods high stood at $893,506 for FY2023, and its period low was $473,426 during FY2022.
  • Moreover, its 3-year median value for Finished Goods was $840,812 (2024), whereas its average is $803,499.
  • Per our database at Business Quant, InMed Pharmaceuticals' Finished Goods soared by 88.73% in 2023 and then decreased by 19.58% in 2025.
  • Yearly analysis of 4 years shows InMed Pharmaceuticals' Finished Goods stood at $473,426 in 2022, then spiked by 88.73% to $893,506 in 2023, then fell by 5.90% to $840,812 in 2024, then dropped by 19.58% to $676,178 in 2025.